GLSH · Gelesis Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11M | $1.75M | - | $6.65M | $2.18M | $3.10M | - | - | - | - |
| Cost of Revenue | $498.0K | $1.24M | - | $2.76M | $2.00M | $2.82M | - | - | - | - |
| Gross Profit | $609.0K | $516.0K | - | $3.89M | $173.0K | $285.0K | - | - | - | - |
| R&D | $2.58M | $3.64M | - | $3.37M | $5.52M | $4.38M | - | - | - | - |
| SG&A | $7.46M | $8.29M | - | $17.03M | $13.97M | $11.95M | - | $1.11M | $0 | - |
| Total Operating Expenses | $11.10M | $13.73M | - | $24.58M | $22.14M | $50.60M | - | - | - | $350.9K |
| D&A | $1.50M | $2.01M | - | $200.0K | $400.0K | $1.02M | - | - | - | - |
| Operating Income | ($10.00M) | ($11.97M) | - | ($17.93M) | ($34.35M) | ($43.08M) | - | ($1.11M) | $0 | ($350.9K) |
| Interest Expense | $565.0K | $891.0K | - | $361.0K | $186.0K | $361.0K | - | - | - | - |
| Income Tax | - | $16.0K | - | $0 | - | $0 | - | $0 | - | - |
| Net Income | ($7.68M) | ($5.15M) | - | ($14.15M) | ($12.51M) | ($5.70M) | - | ($14.26M) | ($4.09M) | $14.69M |
| EPS - Basic | ($0.17) | ($0.07) | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.17) | ($0.07) | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.91M | $3.10M | $7.41M | $24.85M | $25.34M | $33.98M | $221.2K | $304.9K | $791.6K | $947.9K |
| Accounts Receivable | $799.0K | $1.27M | $1.23M | $775.0K | $1.26M | $731.0K | - | - | - | - |
| Inventory | $5.69M | $5.94M | $6.87M | $18.41M | $18.82M | $13.50M | $13.50M | - | - | - |
| Accounts Payable | $9.05M | $7.91M | $4.13M | $7.97M | $22.14M | $13.24M | - | - | - | - |
| Current Assets | $24.68M | $25.42M | $23.50M | $54.70M | $61.65M | $73.07M | $234.7K | $344.8K | $838.3K | $998.6K |
| Total Assets | $95.88M | $98.78M | $103.32M | $130.52M | $138.97M | $152.88M | $276.44M | $276.52M | $276.98M | $277.14M |
| Current Liabilities | $76.54M | $76.19M | $78.35M | $79.80M | $69.28M | $101.54M | - | - | - | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $114.50M | $112.57M | $115.79M | $123.64M | $122.78M | $131.14M | $53.97M | $44.81M | $31.01M | $27.08M |
| Stockholders' Equity | ($31.53M) | ($26.69M) | ($25.06M) | ($3.60M) | $5.10M | $10.04M | ($53.52M) | ($44.31M) | $5.00M | $5.00M |
| Retained Earnings | ($335.56M) | ($327.88M) | ($322.63M) | ($298.13M) | ($283.90M) | ($271.30M) | ($53.52M) | ($44.31M) | ($4.70M) | ($607.9K) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($8.70M) | - | - | - | ($35.18M) | - | - | - | $280.1K |
| Investing Cash Flow | - | ($224.0K) | - | - | - | ($1.96M) | - | - | - | $176.0K |
| Financing Cash Flow | - | $4.59M | - | - | - | $42.78M | - | - | - | - |
| CapEx | - | $224.0K | - | - | - | $6.35M | - | - | - | - |
| Free Cash Flow | - | ($8.92M) | - | - | - | ($41.54M) | - | - | - | - |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 55.0% | 29.4% | - | 58.5% | 7.9% | 9.2% | - | - | - | - |
| Operating margin | -903.0% | -683.1% | - | -269.5% | -1577.2% | -1389.3% | - | - | - | - |
| EBITDA margin | -767.5% | -568.5% | - | -266.5% | -1558.9% | -1356.4% | - | - | - | - |
| Net margin | -693.9% | -293.6% | - | -212.7% | -574.5% | -183.9% | - | - | - | - |
| Free cash flow margin | - | -508.8% | - | - | - | -1339.5% | - | - | - | - |
| FCF / Net income | - | 1.73 | - | - | - | 7.28 | - | - | - | - |
| R&D / Revenue | 233.2% | 207.5% | - | 50.6% | 253.6% | 141.1% | - | - | - | - |
| SG&A / Revenue | 673.5% | 472.7% | - | 256.0% | 641.5% | 385.2% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.0% | -5.2% | - | -10.8% | -9.0% | -3.7% | - | -5.2% | -1.5% | 5.3% |
| Return on equity | 24.4% | 19.3% | - | 393.6% | -245.4% | -56.8% | - | 32.2% | -81.8% | 293.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.32 | 0.33 | 0.30 | 0.69 | 0.89 | 0.72 | - | - | - | - |
| Quick ratio | 0.25 | 0.26 | 0.21 | 0.45 | 0.62 | 0.59 | - | - | - | - |
| Cash ratio | 0.10 | 0.04 | 0.09 | 0.31 | 0.37 | 0.33 | - | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -17.7x | -13.4x | - | -49.7x | -184.7x | -119.3x | - | - | - | - |
| Equity multiplier | -3.04 | -3.70 | -4.12 | -36.31 | 27.26 | 15.23 | -5.16 | -6.24 | 55.40 | 55.43 |
| Liabilities / Assets | 1.19 | 1.14 | 1.12 | 0.95 | 0.88 | 0.86 | 0.20 | 0.16 | 0.11 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | 0.02 | - | 0.05 | 0.02 | 0.02 | - | - | - | - |
| Inventory turnover | 0.09 | 0.21 | - | 0.15 | 0.11 | 0.21 | - | - | - | - |
| Days sales outstanding | 263d | 265d | - | 43d | 210d | 86d | - | - | - | - |
| Days inventory outstanding | 4169d | 1753d | - | 2432d | 3426d | 1750d | - | - | - | - |
| Days payable outstanding | 6634d | 2333d | - | 1053d | 4030d | 1716d | - | - | - | - |
| Cash conversion cycle | -2202d | -315d | - | 1422d | -393d | 120d | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -49.2% | -43.5% | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 252.0% | 81.1% | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 70.9% | 72.2% | - | -1510.3% | - | -12177.4% | - | -503.1% | - | - |
| Net income growth (YoY) | 38.6% | 9.8% | - | 0.7% | -206.0% | - | - | -25497.8% | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 78.5% | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | 53.2% | 91.9% | 2.0% | 100.7% | - | - | 20733.3% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing GELESIS HOLDINGS against the 5 most active filers in the same SIC group.